At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 121 enrolled
Drug / intervention
Bilastine 0.2% +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Center, Double-Masked, Randomized, Vehicle-Controlled, Phase 2, Dose Ranging Evaluation of the Effectiveness of Bilastine Ophthalmic Solution (0.2%, 0.4%, and 0.6%) Compared to Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC®) Model
In Brief
A Phase 2 clinical trial evaluating Bilastine 0.2%, Bilastine 0.4%, and 2 other interventions for Allergic Conjunctivitis. Completed, enrolled 121 participants across 1 site.
Detailed Summary
To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
CountriesUnited States
CollaboratorsORA, Inc.
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartJul 2017
First PostedJul 2017
Primary CompletionOct 2017
TodayJul 2026
First PostedJul 27, 2017
Enrollment StartJul 20, 2017
Primary CompletionOct 11, 2017
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 8.9 years ago
Interventions
Bilastine 0.2%drug
1 drop in each eye at 3 separate times during a 25 day period.
Bilastine 0.4%drug
1 drop in each eye at 3 separate times during a 25 day period.
Bilastine 0.6%drug
1 drop in each eye at 3 separate times during a 25 day period.
Bilastine 0%drug
1 drop in each eye at 3 separate times during a 25 day period.